申请人:Sandoz Ltd.
公开号:US05281605A1
公开(公告)日:1994-01-25
A compound of formula I ##STR1## wherein R.sub.1 is C.sub.1-4 alkyl, C.sub.3-4 alkenyl or (C.sub.3-5 cycloalkyl)-methyl, R.sub.2 is C.sub.1-4 alkyl, [hydroxy- or (C.sub.1-4 alkoxy)-substituted C.sub.1-3 alkyl]-methyl, (C.sub.3-5 cycloalkyl)-methyl, tetrahydrofuran 2-yl-methyl or 1,3-dioxolan-2-yl-methyl, R.sub.3 and R.sub.4 are each hydrogen, hydroxymethyl, methoxymethyl or N,N-dimethylcarbamoyloxymethyl, R.sub.5 is hydroxy or methoxy, R.sub.6 is hydrogen, hydroxy, methoxy or halogen and R.sub.7 is in the 2- or 3-position and is hydroxy, methoxy or halogen, or together with R.sub.5 is 3,4-methylendioxy, or together with R.sub.6 is 2,3-methylenedioxy and their physiologically-hydrolysable and -acceptable esters are useful in the treatment (symptomatic and prophylactic) of obstructive or inflammatory airways disease, in particular asthma, and disease characterised by or having an aetiology comprising morbid eosinophil accumulation or activation, e.g. hypereosinophilia.
化合物的化学式为I ##STR1## 其中R.sub.1为C.sub.1-4烷基,C.sub.3-4烯基或(C.sub.3-5环烷基)-甲基,R.sub.2为C.sub.1-4烷基,[羟基或(C.sub.1-4烷氧基)-取代的C.sub.1-3烷基]-甲基,(C.sub.3-5环烷基)-甲基,四氢呋喃2-基-甲基或1,3-二氧兰-2-基-甲基,R.sub.3和R.sub.4分别为氢,羟甲基,甲氧甲基或N,N-二甲基氨基甲氧甲基,R.sub.5为羟基或甲氧基,R.sub.6为氢,羟基,甲氧基或卤素,R.sub.7在2-或3-位置,为羟基,甲氧基或卤素,或与R.sub.5一起为3,4-亚甲二氧基,或与R.sub.6一起为2,3-亚甲二氧基,它们的生理可水解和可接受的酯类在治疗(症状性和预防性)阻塞性或炎症性呼吸道疾病,特别是哮喘,以及以病态嗜酸性粒细胞积聚或激活为特征或具有上述病因学的疾病中有用。